Compare BON & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BON | IMRN |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 12.0M |
| IPO Year | 2021 | N/A |
| Metric | BON | IMRN |
|---|---|---|
| Price | $1.67 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.8K | ★ 83.4K |
| Earning Date | 01-28-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,670,684.00 | $4,777,422.00 |
| Revenue This Year | $390.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.63 |
| 52 Week Low | $1.14 | $0.68 |
| 52 Week High | $73.75 | $2.39 |
| Indicator | BON | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 46.08 |
| Support Level | $1.61 | $0.93 |
| Resistance Level | $1.73 | $1.05 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 50.13 | 37.43 |
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. Xi'an App-Chem is devoted to providing high quality and competitive prices and a stable supply of products and services for the functional food, personal care, natural medicine and other industries. It provides these products and services for third party customers, as well as for its own proprietary brands. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from Bioactive food ingredients.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.